Fig. 7: C/EBPβ deacetylation reverses hepatic SIRT2 deficiency-aggravated ALD in mice.
From: SIRT2-mediated deacetylation and deubiquitination of C/EBPβ prevents ethanol-induced liver injury
LoxP and SIRT2-KO mice tail injected with AAV8-Ctrl (Ctrl) or AAV8-C/EBPβ (C/EBPβ) or AAV8-C/EBPβ K102R (K102R) or AAV8-C/EBPβ K211R (K211R) were treated with NIAAA model (n = 7/group). a–h The effects of wild-type C/EBPβ or constitutively deacetylated C/EBPβ mutants on steatosis, lipid peroxidation, and cell apoptosis were assessed by images of the indicated livers (scale bar, 1 cm), hepatic H&E staining (scale bar, 50 μm), IHC detection of 4-HNE and TUNEL (scale bar, 100 μm) (a), liver/body weight ratios (b), liver TG (c), hepatic MDA content (d), and PTGS2 mRNA (e), serum ALT (f), and AST (g), quantitative analysis of TUNEL-positive hepatocytes (magnification, ×200) (h). i Hepatic LCN2 mRNA analysis by qRT-PCR. j Western blot analysis of cl.Caspase-3, LCN2, C/EBPβ, and SIRT2 protein expression in the indicated livers. Student’s t-test was used for statistical evaluation. Data are shown as means ± SD and are considered statistically significant at *P < 0.05, **P < 0.01, and ***P < 0.001.
